Johannes Kaesmacher1, Justus F Kleine2. 1. Abteilung für diagnostische und interventionelle Neuroradiologie, Technische Universität München, Ismaninger Str 22, 81675, Munich, Germany. 2. Abteilung für diagnostische und interventionelle Neuroradiologie, Technische Universität München, Ismaninger Str 22, 81675, Munich, Germany. justus.kleine@tum.de.
Abstract
BACKGROUND: Recent studies suggested that preinterventional intravenous (i. v.) recombinant tissue plasminogen activator (rtPA) as bridging therapy facilitates successful and fast vessel recanalization in endovascular stroke treatment (EST); however, data on this effect and the associated clinical value are discrepant. OBJECTIVE: This study examined if this discrepancy could be related to an effect-modifying variable, specifically to the exact occlusion site. METHODS: Retrospective analysis of 239 patients with acute occlusion of the middle cerebral artery (MCA) treated with up to date endovascular techniques. Effects of i. v.-rtPA bridging on clinical outcomes and safety/efficacy of EST, defined as the respective rates of successful, first pass and thrombolysis in cerebral infarction (TICI) scale 3 recanalization, were evaluated and stratified according to distal versus proximal occlusion sites. RESULTS: Overall, i. v.-rtPA bridging was associated with a significantly higher rate of successful recanalization (86.9 % vs. 75.7 %, p = 0.028). i. v.-rtPA bridging-related effects, however, were observable only in distal, but not in proximal MCA-occlusions. In distal occlusions, i. v.-rtPA clearly favored successful recanalization (adj. OR 4.6, 95 %-CI 1.5-13.6, p = 0.006) and first-pass successes (adj. OR 2.8, 95 %-CI 1.0-7.6, p = 0.042), but tended to be associated with lower rates of complete (TICI-3) reperfusion (adj. OR 0.4, 95 %-CI 0.2-1.1, p = 0.068). The net effect was a small clinical benefit, reflected in higher rates of strong neurological improvement (adj. OR: 2.8, 95 %-CI: 1.1-6.9, p = 0.03). CONCLUSION: i. v.-rtPA-bridging-related effects are occlusion site-dependent, paralleling similar effects of systemic i. v.-rtPA when applied without subsequent endovascular therapy. In distal occlusions, i. v.-rtPA facilitates thrombectomy, but may also promote distal embolization, with a small clinical benefit as overall net effect. Randomized trials assessing i.v-rtPA bridging need to be stratified according to occlusions sites.
BACKGROUND: Recent studies suggested that preinterventional intravenous (i. v.) recombinant tissue plasminogen activator (rtPA) as bridging therapy facilitates successful and fast vessel recanalization in endovascular stroke treatment (EST); however, data on this effect and the associated clinical value are discrepant. OBJECTIVE: This study examined if this discrepancy could be related to an effect-modifying variable, specifically to the exact occlusion site. METHODS: Retrospective analysis of 239 patients with acute occlusion of the middle cerebral artery (MCA) treated with up to date endovascular techniques. Effects of i. v.-rtPA bridging on clinical outcomes and safety/efficacy of EST, defined as the respective rates of successful, first pass and thrombolysis in cerebral infarction (TICI) scale 3 recanalization, were evaluated and stratified according to distal versus proximal occlusion sites. RESULTS: Overall, i. v.-rtPA bridging was associated with a significantly higher rate of successful recanalization (86.9 % vs. 75.7 %, p = 0.028). i. v.-rtPA bridging-related effects, however, were observable only in distal, but not in proximal MCA-occlusions. In distal occlusions, i. v.-rtPA clearly favored successful recanalization (adj. OR 4.6, 95 %-CI 1.5-13.6, p = 0.006) and first-pass successes (adj. OR 2.8, 95 %-CI 1.0-7.6, p = 0.042), but tended to be associated with lower rates of complete (TICI-3) reperfusion (adj. OR 0.4, 95 %-CI 0.2-1.1, p = 0.068). The net effect was a small clinical benefit, reflected in higher rates of strong neurological improvement (adj. OR: 2.8, 95 %-CI: 1.1-6.9, p = 0.03). CONCLUSION: i. v.-rtPA-bridging-related effects are occlusion site-dependent, paralleling similar effects of systemic i. v.-rtPA when applied without subsequent endovascular therapy. In distal occlusions, i. v.-rtPA facilitates thrombectomy, but may also promote distal embolization, with a small clinical benefit as overall net effect. Randomized trials assessing i.v-rtPA bridging need to be stratified according to occlusions sites.
Authors: L Behrens; M Möhlenbruch; S Stampfl; P A Ringleb; C Hametner; L Kellert; M Pham; C Herweh; M Bendszus; S Rohde Journal: Eur J Neurol Date: 2014-07-21 Impact factor: 6.089
Authors: J T Saarinen; N Sillanpää; H Rusanen; J Hakomäki; H Huhtala; A Lähteelä; P Dastidar; S Soimakallio; I Elovaara Journal: Eur J Neurol Date: 2012-03-15 Impact factor: 6.089
Authors: Jeffrey L Saver; Mayank Goyal; Alain Bonafe; Hans-Christoph Diener; Elad I Levy; Vitor M Pereira; Gregory W Albers; Christophe Cognard; David J Cohen; Werner Hacke; Olav Jansen; Tudor G Jovin; Heinrich P Mattle; Raul G Nogueira; Adnan H Siddiqui; Dileep R Yavagal; Blaise W Baxter; Thomas G Devlin; Demetrius K Lopes; Vivek K Reddy; Richard du Mesnil de Rochemont; Oliver C Singer; Reza Jahan Journal: N Engl J Med Date: 2015-04-17 Impact factor: 91.245
Authors: Bruce C V Campbell; Peter J Mitchell; Timothy J Kleinig; Helen M Dewey; Leonid Churilov; Nawaf Yassi; Bernard Yan; Richard J Dowling; Mark W Parsons; Thomas J Oxley; Teddy Y Wu; Mark Brooks; Marion A Simpson; Ferdinand Miteff; Christopher R Levi; Martin Krause; Timothy J Harrington; Kenneth C Faulder; Brendan S Steinfort; Miriam Priglinger; Timothy Ang; Rebecca Scroop; P Alan Barber; Ben McGuinness; Tissa Wijeratne; Thanh G Phan; Winston Chong; Ronil V Chandra; Christopher F Bladin; Monica Badve; Henry Rice; Laetitia de Villiers; Henry Ma; Patricia M Desmond; Geoffrey A Donnan; Stephen M Davis Journal: N Engl J Med Date: 2015-02-11 Impact factor: 91.245
Authors: Peter Sandercock; Joanna M Wardlaw; Richard I Lindley; Martin Dennis; Geoff Cohen; Gordon Murray; Karen Innes; Graham Venables; Anna Czlonkowska; Adam Kobayashi; Stefano Ricci; Veronica Murray; Eivind Berge; Karsten Bruins Slot; Graeme J Hankey; Manuel Correia; Andre Peeters; Karl Matz; Phillippe Lyrer; Gord Gubitz; Stephen J Phillips; Antonio Arauz Journal: Lancet Date: 2012-05-23 Impact factor: 79.321
Authors: Johannes Kaesmacher; Christian Maegerlein; Felix Zibold; Silke Wunderlich; Claus Zimmer; Benjamin Friedrich Journal: Eur Radiol Date: 2017-07-27 Impact factor: 5.315
Authors: Carmen Serna Candel; Marta Aguilar Pérez; Victoria Hellstern; Muhammad AlMatter; Hansjörg Bäzner; Hans Henkes Journal: Cerebrovasc Dis Date: 2019-11-20 Impact factor: 2.762
Authors: Muhammad Umer Azeem; Muhammad Nagy; Malgorzata M Miller; Mehdi Ghasemi; Abdul Mikati; Brian Silver; Majaz Moonis; Nils Henninger Journal: J Stroke Cerebrovasc Dis Date: 2020-02-21 Impact factor: 2.136
Authors: Johannes Kaesmacher; Christian Maegerlein; Mirjam Kaesmacher; Claus Zimmer; Holger Poppert; Benjamin Friedrich; Tobias Boeckh-Behrens; Justus F Kleine Journal: J Am Heart Assoc Date: 2017-02-15 Impact factor: 5.501
Authors: Vicky Chalos; Natalie E LeCouffe; Maarten Uyttenboogaart; Hester F Lingsma; Maxim J H L Mulder; Esmee Venema; Kilian M Treurniet; Omid Eshghi; H Bart van der Worp; Aad van der Lugt; Yvo B W E M Roos; Charles B L M Majoie; Diederik W J Dippel; Bob Roozenbeek; Jonathan M Coutinho Journal: J Am Heart Assoc Date: 2019-05-29 Impact factor: 5.501